Pacific Biosciences of California (PACB) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Pacific Biosciences (PACB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend rever…

Pacific Biosciences reported mixed Q3 results, with revenues beating reduced estimates but gross margins falling. Despite continually declining street revenue estimates, management was disappointed with guidance as it tr…

Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript…

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.12 per share a year ago.…

Pacific Biosciences of California NASDAQ: PACB reported 6% revenue growth for the third quarter of 2026 as customers adopted its SPRQ-Nx sequencing chemistry, though consumables revenue declined from a year earlier and a…

MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026.…

In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.9, marking a +2.47% move from the previous day.…

MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the followi…

PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.…

The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.06, representing a -3.74% change from its previous close.…

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.…

MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 20…

PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.…

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) shares gapped down before the market opened on Monday. The stock had previously closed at $2.33, but opened at $2.24. Pacific Biosciences of Califo…

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) insider James Gibson II sold 661,815 shares of Pacific Biosciences of California stock in a transaction that occurred on Tuesday, October 6th. The …

The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.…

Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.…

Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.…

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 13,687 call options on the stock. This represents an in…

Shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) rose 6.1% on Monday. The company traded as high as $1.68 and last traded at $1.7190. 2,798,059 shares traded hands during mid-day trading…

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.…

Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics,…

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.…

MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat…
No recent releases where the company itself is speaking.
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 12. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

